117 related articles for article (PubMed ID: 10697612)
1. 37 kiloDalton oncofetal antigen protein and immature laminin receptor protein are identical, universal T-cell inducing immunogens on primary rodent and human cancers.
Coggin JH; Barsoum AL; Rohrer JW
Anticancer Res; 1999; 19(6C):5535-42. PubMed ID: 10697612
[TBL] [Abstract][Full Text] [Related]
2. Production, safety and antitumor efficacy of recombinant Oncofetal Antigen/immature laminin receptor protein.
Barsoum AL; Liu B; Rohrer JW; Coggin JH; Tucker JA; Pannell LK; Schwarzenberger PO
Biomaterials; 2009 Jun; 30(17):3091-9. PubMed ID: 19268360
[TBL] [Abstract][Full Text] [Related]
3. Human breast carcinoma patients develop clonable oncofetal antigen-specific effector and regulatory T lymphocytes.
Rohrer JW; Barsoum AL; Dyess DL; Tucker JA; Coggin JH
J Immunol; 1999 Jun; 162(11):6880-92. PubMed ID: 10352310
[TBL] [Abstract][Full Text] [Related]
4. Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies.
Siegel S; Wagner A; Kabelitz D; Marget M; Coggin J; Barsoum A; Rohrer J; Schmitz N; Zeis M
Blood; 2003 Dec; 102(13):4416-23. PubMed ID: 12869512
[TBL] [Abstract][Full Text] [Related]
5. Identification of oncofetal antigen/immature laminin receptor protein epitopes that activate BALB/c mouse OFA/iLRP-specific effector and regulatory T cell clones.
Rohrer JW; Barsoum AL; Coggin JH
J Immunol; 2006 Mar; 176(5):2844-56. PubMed ID: 16493041
[TBL] [Abstract][Full Text] [Related]
6. Characterization of RFM mouse T lymphocyte anti-oncofetal antigen immunity in apparent tumor-free, long-term survivors of sublethal X-irradiation by limiting dilution T lymphocyte cloning.
Rohrer JW; Culpepper C; Barsoum AL; Coggin JH
J Immunol; 1995 Mar; 154(5):2266-80. PubMed ID: 7868899
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies specific for oncofetal antigen--immature laminin receptor protein: Effects on tumor growth and spread in two murine models.
McClintock SD; Warner RL; Ali S; Chekuri A; Dame MK; Attili D; Knibbs RK; Aslam MN; Sinkule J; Morgan AC; Barsoum A; Smith LB; Beer DG; Johnson KJ; Varani J
Cancer Biol Ther; 2015; 16(5):724-32. PubMed ID: 25799942
[TBL] [Abstract][Full Text] [Related]
8. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow.
Feuerer M; Beckhove P; Bai L; Solomayer EF; Bastert G; Diel IJ; Pedain C; Oberniedermayr M; Schirrmacher V; Umansky V
Nat Med; 2001 Apr; 7(4):452-8. PubMed ID: 11283672
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a soluble partially purified oncofetal antigen from murine fibrosarcoma in syngeneic mice.
Barsoum AL; Coggin JH
J Biol Response Mod; 1989 Dec; 8(6):579-92. PubMed ID: 2600602
[TBL] [Abstract][Full Text] [Related]
10. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.
Cohen CJ; Hoffmann N; Farago M; Hoogenboom HR; Eisenbach L; Reiter Y
Cancer Res; 2002 Oct; 62(20):5835-44. PubMed ID: 12384546
[TBL] [Abstract][Full Text] [Related]
11. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
[TBL] [Abstract][Full Text] [Related]
12. Expression and immunogenicity of oncofetal antigen-immature laminin receptor in human renal cell carcinoma.
Zelle-Rieser C; Barsoum AL; Sallusto F; Ramoner R; Rohrer JW; Höltl L; Bartsch G; Coggin JH JR; Thurnher M
J Urol; 2001 May; 165(5):1705-9. PubMed ID: 11342960
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.
Rentzsch C; Kayser S; Stumm S; Watermann I; Walter S; Stevanoviç S; Wallwiener D; Gückel B
Clin Cancer Res; 2003 Oct; 9(12):4376-86. PubMed ID: 14555509
[TBL] [Abstract][Full Text] [Related]
14. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
15. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
16. Identification of partial complementary DNA clones encoding a 59-kd protein with characteristics of a unique oncofetal antigen.
Rashid HU; Barsoum AL; Cao TM; Coggin JH
J Natl Cancer Inst; 1994 Apr; 86(7):515-26. PubMed ID: 8133535
[TBL] [Abstract][Full Text] [Related]
17. Structure-function studies of the functional and binding epitope of the human 37 kDa laminin receptor precursor protein.
Jaseja M; Mergen L; Gillette K; Forbes K; Sehgal I; Copié V
J Pept Res; 2005 Jul; 66(1):9-18. PubMed ID: 15946191
[TBL] [Abstract][Full Text] [Related]
18. The nonintegrin laminin binding protein (p67 LBP) is expressed on a subset of activated human T lymphocytes and, together with the integrin very late activation antigen-6, mediates avid cellular adherence to laminin.
Canfield SM; Khakoo AY
J Immunol; 1999 Sep; 163(6):3430-40. PubMed ID: 10477615
[TBL] [Abstract][Full Text] [Related]
19. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.
Hirohashi Y; Torigoe T; Maeda A; Nabeta Y; Kamiguchi K; Sato T; Yoda J; Ikeda H; Hirata K; Yamanaka N; Sato N
Clin Cancer Res; 2002 Jun; 8(6):1731-9. PubMed ID: 12060610
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
